Literature DB >> 20482521

Maternal blood serum and plasma human tumor-associated antigen RCAS1 during the course of uncomplicated pregnancies: a prospective study.

Ekaterine Tskitishvili1, Namuxila Sharentuya, Hiroaki Tsubouchi, Yukiko Kinugasa-Taniguchi, Takeshi Kanagawa, Koichiro Shimoya, Takuji Tomimatsu, Tadashi Kimura.   

Abstract

PROBLEM: we aimed to investigate the expression of the tumor-associated RCAS1 protein in maternal blood of uncomplicated pregnancies. METHOD OF STUDY: maternal blood was obtained from women with uncomplicated pregnancies (N = 43) at 11-13, 20-22, 32-34, 37-38 weeks of gestation, and immediately after delivery. Serum RCAS1 concentration was studied by ELISA, and plasma mRNA was subjected to real-time (RT)-PCR.
RESULTS: serum RCAS1 protein concentration was significantly up-regulated at 11-13 and 20-22 weeks than that at 32-34 weeks and after delivery. RCAS1 mRNA level was significantly increased at 11-13 weeks than that at 37-38 weeks. A significant positive correlation was defined between RCAS1 serum concentration at 11-13 weeks and gestational age at delivery and that between plasma RCAS1 mRNA levels at 37-38 weeks and umbilical cord blood base excess. A significant negative correlation was found between RCAS1 serum concentration at 37-38 weeks and umbilical cord blood pH at delivery.
CONCLUSIONS: RCAS1 protein might have importance in the development of uncomplicated pregnancies and for the prediction of pregnancy outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20482521     DOI: 10.1111/j.1600-0897.2010.00859.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  1 in total

1.  Analysis of the intensity of immune cell infiltration and immunoreactivity of RCAS1 in diffuse large B-cell lymphoma of the palatine tonsil and its microenvironment.

Authors:  W Kazmierczak; A Lazar; R Tomaszewska; T J Popiela; K Koper; Lukasz Wicherek; M Dutsch-Wicherek
Journal:  Cell Tissue Res       Date:  2015-03-17       Impact factor: 5.249

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.